TY - JOUR
T1 - Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease
AU - Docampo, Melissa D.
AU - da Silva, Marina B.
AU - Lazrak, Amina
AU - Nichols, Katherine B.
AU - Lieberman, Sophia R.
AU - Slingerland, Ann E.
AU - Armijo, Gabriel K.
AU - Shono, Yusuke
AU - Nguyen, Chi
AU - Monette, Sebastien
AU - Dwomoh, Emmanuel
AU - Lee, Nicole
AU - Geary, Clair D.
AU - Perobelli, Suelen M.
AU - Smith, Melody
AU - Markey, Kate A.
AU - Vardhana, Santosha A.
AU - Kousa, Anastasia I.
AU - Zamir, Eli
AU - Greenfield, Itamar
AU - Sun, Joseph C.
AU - Cross, Justin R.
AU - Peled, Jonathan U.
AU - Jenq, Robert R.
AU - Stein-Thoeringer, Christoph K.
AU - van den Brink, Marcel R.M.
N1 - Funding Information:
J.U.P. reports funding from NHLBI NIH Award K08HL143189, the MSKCC Cancer Center Core Grant NCI P30 CA008748. This research was supported by the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, J.U.P is a member of the Parker Institute for Cancer Immunotherapy. M.R.M.v.d.B. reports funding by National Cancer Institute award numbers, R01-CA228358, R01-CA228308, R01-HL147584, P30 CA008748 MSK Cancer Center Support Grant/Core Grant, and Project 2 of P01-CA023766, National Heart, Lung, and Blood Institute (NHLBI) award numbers R01-HL125571 (A. Hanash) and R01-HL123340 (K. Cadwell), National Institute of Aging award number Project 2 of P01-AG052359 (J. Nikolich-Zugich/M.v.d.B.), National Institute of Allergy and Infectious Diseases award number U01 AI124275. Additional funding was received from The Lymphoma Foundation, The Susan and Peter Solomon Divisional Genomics Program, Starr Cancer Consortium, Tri-Institutional Stem Cell Initiative, Cycle for Survival, and the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center. The authors thank Klaus Pfeffer (University of Dusseldorf) for providing the Gpr109a−/− mice and Ikuo Kimura (Kyoto University) for providing the Gpr43−/− mice.
Funding Information:
J.U.P. reports funding from NHLBI NIH Award K08HL143189, the MSKCC Cancer Center Core Grant NCI P30 CA008748. This research was supported by the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center, J.U.P is a member of the Parker Institute for Cancer Immunotherapy. M.R.M.v.d.B. reports funding by National Cancer Institute award numbers, R01-CA228358, R01-CA228308, R01-HL147584, P30 CA008748 MSK Cancer Center Support Grant/Core Grant, and Project 2 of P01-CA023766, National Heart, Lung, and Blood Institute (NHLBI) award numbers R01-HL125571 (A. Hanash) and R01-HL123340 (K. Cadwell), National Institute of Aging award number Project 2 of P01-AG052359 (J. Nikolich-Zugich/M.v.d.B.), National Institute of Allergy and Infectious Diseases award number U01 AI124275. Additional funding was received from The Lymphoma Foundation, The Susan and Peter Solomon Divisional Genomics Program, Starr Cancer Consortium, Tri-Institutional Stem Cell Initiative, Cycle for Survival, and the Parker Institute for Cancer Immunotherapy at Memorial Sloan Kettering Cancer Center.
Publisher Copyright:
© 2022 American Society of Hematology
PY - 2022/4/14
Y1 - 2022/4/14
N2 - The intestinal microbiota is essential for the fermentation of dietary fiber into short-chain fatty acids (SCFA) such as butyrate, acetate, and propionate. SCFAs can bind to the G-protein-coupled receptors GPR43 and GPR109A (HCAR2), with varying affinities to promote cellular effects in metabolism or changes in immune function. We explored the role of GPR109A as the main receptor for butyrate in mouse models of allogeneic hematopoietic cell transplantation (allo-HCT) and graft-versus-host disease (GVHD). Deletion of GPR109A in allo-HCT recipients did not affect GVHD, but transplantation of T cells from GPR109A knockout (KO) (Gpr109a−/−) mice into allo-HCT recipient mice significantly reduced GVHD morbidity and mortality compared with recipients of wild-type (WT) T cells. Recipients of Gpr109a−/− T cells exhibited less GVHD-associated target organ pathology and decreased proliferation and homing of alloreactive T cells to target tissues. Although Gpr109a−/− T cells did not exhibit immune deficits at a steady state, following allo-activation, Gpr109a−/− T cells underwent increased apoptosis and were impaired mitochondrial oxidative phosphorylation, which was reversible through antioxidant treatment with N-acetylcysteine (NAC). In conclusion, we found that GPR109A expression by allo-activated T cells is essential for metabolic homeostasis and expansion, which are necessary features to induce GVHD after allo-HCT.
AB - The intestinal microbiota is essential for the fermentation of dietary fiber into short-chain fatty acids (SCFA) such as butyrate, acetate, and propionate. SCFAs can bind to the G-protein-coupled receptors GPR43 and GPR109A (HCAR2), with varying affinities to promote cellular effects in metabolism or changes in immune function. We explored the role of GPR109A as the main receptor for butyrate in mouse models of allogeneic hematopoietic cell transplantation (allo-HCT) and graft-versus-host disease (GVHD). Deletion of GPR109A in allo-HCT recipients did not affect GVHD, but transplantation of T cells from GPR109A knockout (KO) (Gpr109a−/−) mice into allo-HCT recipient mice significantly reduced GVHD morbidity and mortality compared with recipients of wild-type (WT) T cells. Recipients of Gpr109a−/− T cells exhibited less GVHD-associated target organ pathology and decreased proliferation and homing of alloreactive T cells to target tissues. Although Gpr109a−/− T cells did not exhibit immune deficits at a steady state, following allo-activation, Gpr109a−/− T cells underwent increased apoptosis and were impaired mitochondrial oxidative phosphorylation, which was reversible through antioxidant treatment with N-acetylcysteine (NAC). In conclusion, we found that GPR109A expression by allo-activated T cells is essential for metabolic homeostasis and expansion, which are necessary features to induce GVHD after allo-HCT.
UR - http://www.scopus.com/inward/record.url?scp=85127090021&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85127090021&partnerID=8YFLogxK
U2 - 10.1182/blood.2021010719
DO - 10.1182/blood.2021010719
M3 - Article
C2 - 34653248
AN - SCOPUS:85127090021
VL - 139
SP - 2392
EP - 2405
JO - Blood
JF - Blood
SN - 0006-4971
IS - 15
ER -